Suppr超能文献

活化自然杀伤细胞对小儿实体瘤的细胞毒性。

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

机构信息

Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.

出版信息

Clin Cancer Res. 2010 Aug 1;16(15):3901-9. doi: 10.1158/1078-0432.CCR-10-0735. Epub 2010 Jun 11.

Abstract

PURPOSE

To develop new therapies for children with solid tumors, we tested the cytotoxicity of natural killer (NK) cells expanded by coculture with K562-mb15-41BBL cells. We sought to identify the most sensitive tumor subtypes, clarify the molecular interactions regulating cytotoxicity, and determine NK antitumor potential in vivo.

EXPERIMENTAL DESIGN

We tested in vitro cytotoxicity of expanded NK cells against cell lines representative of Ewing sarcoma (EWS; n = 5), rhabdomyosarcoma (n = 4), neuroblastoma (n = 3), and osteosarcoma (n = 3), and correlated the results with expression of inhibitory and activating NK receptor ligands. We also compared expanded and primary NK cells, determined the effects of activating receptor ligation and of chemotherapeutic drugs, and assessed the therapeutic effect of NK cell infusions in xenografts.

RESULTS

In 45 experiments, EWS and rhabdomyosarcoma cell lines were remarkably sensitive to expanded NK cells, with median cytotoxicities at 1:1 effector/target ratio of 87.2% and 79.1%, respectively. Cytotoxicity was not related to levels of expression of NK receptor ligands, nor was it affected by pretreatment of target cells with daunorubicin or vincristine, but was markedly inhibited by preincubation of NK cells with a combination of antibodies against the NK-activating receptors NKGD2 and DNAM-1. Expanded NK cells were considerably more cytotoxic than unstimulated NK cells, and eradicated EWS cells engrafted in nonobese diabetic/severe combined immunodeficient Il2rgnull mice.

CONCLUSIONS

Among pediatric solid tumors, EWS and rhabdomyosarcoma are exquisitely sensitive to expanded NK cells. The NK expansion method described here has been adapted to large-scale conditions and supports a phase I clinical study including patients with these malignancies.

摘要

目的

为了开发针对儿童实体瘤的新疗法,我们测试了与 K562-mb15-41BBL 细胞共培养扩增的自然杀伤 (NK) 细胞的细胞毒性。我们试图确定最敏感的肿瘤亚型,阐明调节细胞毒性的分子相互作用,并确定 NK 在体内的抗肿瘤潜力。

实验设计

我们测试了体外扩增的 NK 细胞对代表尤文肉瘤 (EWS; n = 5)、横纹肌肉瘤 (n = 4)、神经母细胞瘤 (n = 3)和骨肉瘤 (n = 3)的细胞系的细胞毒性,并将结果与抑制性和激活性 NK 受体配体的表达相关联。我们还比较了扩增和原代 NK 细胞,确定了激活受体配体结合和化疗药物的影响,并评估了 NK 细胞输注在异种移植物中的治疗效果。

结果

在 45 次实验中,EWS 和横纹肌肉瘤细胞系对扩增的 NK 细胞非常敏感,在 1:1 效应物/靶比时的中位细胞毒性分别为 87.2%和 79.1%。细胞毒性与 NK 受体配体的表达水平无关,也不受达那霉素或长春新碱预处理靶细胞的影响,但被 NK 细胞与 NK-激活受体 NKGD2 和 DNAM-1 的组合抗体预孵育显著抑制。扩增的 NK 细胞比未刺激的 NK 细胞具有更强的细胞毒性,并根除了植入非肥胖型糖尿病/严重联合免疫缺陷 Il2rgnull 小鼠的 EWS 细胞。

结论

在儿科实体瘤中,EWS 和横纹肌肉瘤对扩增的 NK 细胞极为敏感。本文描述的 NK 扩增方法已适应大规模条件,并支持包括这些恶性肿瘤患者在内的 I 期临床试验。

相似文献

1
Cytotoxicity of activated natural killer cells against pediatric solid tumors.
Clin Cancer Res. 2010 Aug 1;16(15):3901-9. doi: 10.1158/1078-0432.CCR-10-0735. Epub 2010 Jun 11.
2
Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
Front Immunol. 2021 Nov 4;12:791206. doi: 10.3389/fimmu.2021.791206. eCollection 2021.
3
Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Cancer Immunol Res. 2016 Jul;4(7):574-81. doi: 10.1158/2326-6066.CIR-15-0229. Epub 2016 May 13.
4
Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
Clin Cancer Res. 2013 Apr 15;19(8):2132-43. doi: 10.1158/1078-0432.CCR-12-1243. Epub 2013 Feb 1.
5
Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer.
Int J Cancer. 2014 Sep 15;135(6):1390-8. doi: 10.1002/ijc.28780. Epub 2014 Feb 28.
6
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
Mol Immunol. 2008 Sep;45(15):3917-25. doi: 10.1016/j.molimm.2008.06.016. Epub 2008 Jul 26.
8
Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Front Immunol. 2020 Jan 28;11:40. doi: 10.3389/fimmu.2020.00040. eCollection 2020.
10
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.
Cancer Res. 2009 May 1;69(9):4010-7. doi: 10.1158/0008-5472.CAN-08-3712. Epub 2009 Apr 21.

引用本文的文献

3
Combinatorial immunotherapy of anti-MCAM CAR-modified expanded natural killer cells and NKTR-255 against neuroblastoma.
Mol Ther Oncol. 2024 Oct 18;32(4):200894. doi: 10.1016/j.omton.2024.200894. eCollection 2024 Dec 19.
4
Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy.
J Immunother Cancer. 2024 Sep 12;12(9):e009726. doi: 10.1136/jitc-2024-009726.
5
Improvement of histone deacetylase inhibitor efficacy by SN38 through TWIST1 suppression in synovial sarcoma.
Cancer Innov. 2024 Apr 8;3(2):e113. doi: 10.1002/cai2.113. eCollection 2024 Apr.
6
Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 and in NB xenografts.
Mol Ther Oncol. 2024 May 24;32(2):200820. doi: 10.1016/j.omton.2024.200820. eCollection 2024 Jun 20.
8
A Functional Chemiluminescent Probe for in Vivo Imaging of Natural Killer Cell Activity Against Tumours.
Angew Chem Weinheim Bergstr Ger. 2021 Mar 8;133(11):5763-5767. doi: 10.1002/ange.202011429. Epub 2021 Feb 2.
9
Genomic nursing science revealed the prolyl 4-hydroxylase subunit alpha 2 as a significant biomarker involved in osteosarcoma.
Heliyon. 2024 Feb 29;10(5):e27191. doi: 10.1016/j.heliyon.2024.e27191. eCollection 2024 Mar 15.
10
Intensified NK cell therapy in combination with low-dose chemoradiotherapy against human colorectal cancer.
Cancer Immunol Immunother. 2023 Dec;72(12):4089-4102. doi: 10.1007/s00262-023-03545-w. Epub 2023 Oct 6.

本文引用的文献

2
Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method.
Cancer Gene Ther. 2010 Mar;17(3):147-54. doi: 10.1038/cgt.2009.61. Epub 2009 Sep 11.
5
Bone tumors: osteosarcoma and Ewing's sarcoma.
Curr Opin Pediatr. 2009 Jun;21(3):365-72. doi: 10.1097/MOP.0b013e32832b1111.
6
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.
Cancer Res. 2009 May 1;69(9):4010-7. doi: 10.1158/0008-5472.CAN-08-3712. Epub 2009 Apr 21.
7
Replicative potential of human natural killer cells.
Br J Haematol. 2009 Jun;145(5):606-13. doi: 10.1111/j.1365-2141.2009.07667.x. Epub 2009 Mar 26.
10
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
Mol Immunol. 2008 Sep;45(15):3917-25. doi: 10.1016/j.molimm.2008.06.016. Epub 2008 Jul 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验